Nodal, a member of the transforming growth factor-b superfamily, has been recently shown to suppress cell proliferation and to stimulate the expression of cyclin G2 (CCNG2) in human epithelial ovarian cancer cells. However, the precise mechanisms underlying these events are not fully understood. In this study, we investigated the transcriptional regulation of CCNG2 by the Nodal signaling pathway. In ovarian cancer cells, overexpression of Nodal or its receptors, activin receptorlike kinase 7 (ALK7) or ALK4, resulted in an increase in the CCNG2 promoter activity. Several putative Forkhead box class O (FoxO)3a-binding sites are present in the human CCNG2 promoter and overexpression of FoxO3a enhanced the CCNG2 promoter activity. The functional FoxO3a-binding element (FBE) was mapped to a proximal region located between À398 and À380 bp (FBE1) through deletion and mutation analyses, as well as chromatin immunoprecipitation (IP) assay. Interestingly, mutation of the FBE1 not only abolished the effect of FoxO3a, but also blocked Nodal-induced CCNG2 transcription. Nodal stimulated FoxO3a mRNA and protein expression through the canonical Smad pathway and suppressed FoxO3a inactivation by inhibiting AKT activity. Silencing of FoxO3a using small interfering RNA significantly reduced the effect of Nodal on the CCNG2 promoter activity. On the other hand, overexpression of Smad2 and Smad3 enhanced the FoxO3a-induced CCNG2 promoter activity whereas knockdown of Smad4 blocked the activity of FoxO3a. Furthermore, IP assays revealed that FoxO3a formed complexes with Smad proteins and that Nodal enhanced the binding of FoxO3a to the CCNG2 promoter. Finally, silencing of FoxO3a reversed the inhibitory effect of Nodal on cell proliferation. Taken together, these findings demonstrated that Nodal signaling promotes CCNG2 transcription by upregulating FoxO3a expression, inhibiting FoxO3a phosphorylation and enhancing its synergistic interaction with Smads. These results also suggest that FoxO3a is an important mediator of Nodal signaling in ovarian cancer cells.
Introduction
Nodal, a member of the transforming growth factor-b (TGF-b) family, has essential roles during embryogenesis, such as formation of mesoderm and patterning of left-right axis (Schier and Shen, 2000; Shen, 2007; Baker et al., 2008) . Recently, we have shown that Nodal and its receptors, activin receptor-like kinase 7 (ALK7) and ALK4, are expressed in human ovarian cancer cells . Furthermore, Nodal was also detected in rat ovarian follicular cells, normal and malignant human endometrial cells (Papageorgiou et al., 2009) , lactating mammary (Kenney et al., 2004) and breast cancer cells (Strizzi et al., 2008) , as well as islet cells in the pancreas (Zhang et al., 2008) . The expression of Nodal in a variety of tissues suggests the extension of its biological function beyond embryo development. Indeed, Nodal has been reported to inhibit proliferation and induce apoptosis in human trophoblast cells , human ovarian cancer cells (Xu et al., , 2008 , rat ovarian granulosa cells and murine and human pancreatic b-cells (Zhang et al., 2008) . In contrast, Nodal promotes stem cell self-renewal (Ogawa et al., 2007) and melanoma tumorigenicity (Topczewska et al., 2006) .
The canonical Nodal signaling resembles the TGF-b/ Smad pathway (Kumar et al., 2001; Derynck and Zhang, 2003; Massague et al., 2005) . Nodal binds to a membrane serine/threonine kinase receptor complex consisting of type I (ALK4 or ALK7) and type II (ActRIIA or ActRIIB) serine/theronine kinase receptors to activate Smad2 and Smad3 (Kumar et al., 2001; Reissmann et al., 2001) . The phosphorylated Smad2/3 proteins bind to Smad4 and subsequently undergo nuclear translocation, allowing for the assembly of active transcription complexes on the promoter of Nodal target genes (Schier, 2003; Massague et al., 2005) .
Human cyclin G2 (CCNG2) belongs to the 'G' family of unconventional cyclins (Bates et al., 1996; Horne et al., 1996) . Unlike other cyclins that function to promote cell cycle progression, CCNG2 has not been detected to form complexes with any cyclin-dependent protein kinases. Instead, CCNG2 inhibits cell cycle progression possibly through interacting with the catalytic and regulatory subunits of protein phosphatase 2A (Bennin et al., 2002) . CCNG2 has a short half-life and it is quickly degraded through the ubiquitinproteasome pathway (Xu et al., 2008) , providing a way by which arrested or quiescent cells may re-enter the cell cycle. Ectopic expression of the CCNG2 inhibited cell proliferation and induced cell cycle arrest in murine B cells (Horne et al., 1997) , HEK293, Chinese hamster ovary cells (Bennin et al., 2002) and several cancer cell lines (Kim et al., 2004; Le et al., 2007; Xu et al., 2008) . In breast cancer cells, CCNG2 expression is inhibited by HER2 through multiple intracellular pathways, including phosphoinositide 3-kinase (PI3K), c-jun NH2-terminal kinase and the mammalian target of rapamycin (Le et al., 2007) .
FoxO3a is a member of the Forkhead box class O (FoxO) transcription factor family (Anderson et al., 1998; Huang and Tindall, 2007) . FoxO transcription factors regulate diverse cell functions (Accili and Arden, 2004) through regulation of genes involved in cell proliferation and apoptosis (Weidinger et al., 2008) . Specifically, FoxO3a has been reported to activate genes that induce cell cycle arrest, such as p27 (Dijkers et al., 2000) , p21 (Seoane et al., 2004) , p15 and p19 (Katayama et al., 2008) , and to suppress the expression of cyclin D2 (Fernandez de Mattos et al., 2004) . FoxO3a is also involved in apoptosis by activating proapoptotic genes Bim (Sunters et al., 2003) , Puma (You et al., 2006) , TRAIL (Cornforth et al., 2008) and Fas ligand (Brunet et al., 1999) . Inhibition of FoxO3a expression promotes cell transformation, tumor progression and angiogenesis, indicating that FoxO3a has tumor-suppressive roles (Ramaswamy et al., 2002) . The activity of FoxO3a is mainly regulated at the level of posttranslational modifications, such as phosphorylation (Brunet et al., 1999; Hu et al., 2004) , deacetylation (Brunet et al., 2004) and degradation . Activation of PI3K/AKT and IkappaB kinase/nuclear factor-kB signaling cascades in response to growth stimuli leads to FoxO3a phosphorylation and subsequent nucleus exclusion.
Previously, we have reported that Nodal acts through ALK7 to inhibit proliferation in immortalized ovarian epithelial cells and in epithelial ovarian cancer cells and that the antiproliferative effect of Nodal in ovarian cells is in part mediated by an upregulation of CCNG2 expression (Xu et al., 2008) . In this study, we investigated how Nodal signaling regulates CCNG2 expression at the level of transcription. We report here that Nodal increased CCNG2 transcription via FoxO3a.
Results
Nodal enhances CCNG2 transcription in human ovarian cancer cells Previously, we have observed that overexpression of Nodal or activation of ALK7 resulted in an increase in CCNG2 mRNA levels (Xu et al., 2008) . To investigate the molecular mechanisms by which Nodal induces CCNG2 gene expression in human ovarian cancer cells, we generated CCNG2 promoter constructs and performed luciferase assays. In OV2008 cells, overexpression of Nodal resulted in a significant increase in CCNG2 promoter activity (Figure 1a) . Similarly, transfection with constitutively active receptor constructs, ALK7ca or ALK4ca, also increased the luciferase activity (Figure 1b) . Furthermore, treatment with recombinant human Nodal (rhNodal) enhanced CCNG2 mRNA (Figure 1c ) and protein (Figure 1d ) levels. LY294002, a PI3K inhibitor, also increased CCNG2 protein levels (Figure 1d ). On the other hand, SB431542, an ALK4/5/7 kinase inhibitor (Matsuyama et al., 2003) , decreased CCNG2 protein expression (Figure 1d ).
CCNG2 gene is a transcriptional target of FoxO3a
To determine how Nodal regulates CCNG2 transcription, we searched for transcription factor-binding sites on the CCNG2 promoter and identified a consensus FoxO-binding site (FBE3, 5 0 -GTAAACA-3 0 ) (Lin et al., 1997; Furuyama et al., 2000) , at position À1345 to À1338 bp (Supplementary Figure 1) . Furthermore, a core FoxO3a-binding motif 5 0 -AAACA-3 0 (Tsai et al., 2007) was found in the promoter region at position À1139 to À1134 bp (FBE2) and three tandem repeats of this core motif were also observed in the region between À398 and À380 bp (FBE1), (Supplementary Figure 1) . We also found several Smad-binding sites (5 0 -AGAC-3 0 ) within the CCNG2 promoter, two of which are in close proximity with FBEs. As FoxO transcription factors are able to interact with Smads to regulate gene expression (Seoane et al., 2004) , we hypothesized that Nodal induces CCNG2 via FoxO3a and its interaction with Smads. To test this hypothesis, we first examined if FoxO3a-induced CCNG2 transcription. Overexpression of wild-type FoxO3a (FoxO3a-WT) and its constitutive activated form, FoxO3a-AAA, which has mutations at the AKT phosphorylation sites (Kops et al., 1999; Ramaswamy et al., 2002) , increased the CCNG2 promoter activity in a dose-and time-dependent manner in OV2008 cells (Figures 2a and b) . Since FoxO3a is inactivated by AKT signaling, we also tested whether blocking PI3K pathway would affect CCNG2 transcription. As shown in Figure 2c , LY294002 caused a dosedependent increase in the luciferase activity. We next performed promoter deletion analysis to delineate the FoxO3a and Nodal responsive regions in the CCNG2 promoter (Figure 3a) . Overexpression of FoxO3a-WT and -AAA (Figure 3b ) or Nodal (Figure 3c ) induced the activity of the full-length promoter (À1491 bp, F6), and the inducing effect was maintained at a similar level when deleting upstream portions of the promoter until the region À601 bp (Figure 3b ), suggesting that the FBE3 and FBE2, and Smad-binding elements (SBEs) located in this region are not functional in mediating FoxO3a and Nodal induction of CCNG2 gene transcription. Further deletion of the promoter region from À601 to À361 bp caused a significant decrease in the basal and FoxO3a-and Nodal-induced CCNG2 promoter activity (Figure 3b ). To confirm that the FBE1 is critical in FoxO3a-and Nodal-regulated CCNG2 transcription, a mutant F3 construct was generated (Figure 3c ). When compared with the WT F3 construct, mutation of the FBE1 significantly decreased the basal, as well as FoxO3a-, LY294002-and Nodal-induced promoter activity (Figure 3c ).
Nodal increases FoxO3a activity and expression
It is known that FoxO3a phosphorylation and nuclear export occur following activation of oncogenic kinases such as AKT and IkappaB kinase (Hu et al., 2004) . To further determine whether Nodal regulates CCNG2 transcription through FoxO3a activation, we investigated whether Nodal and its receptors modulate FoxO3a activity. Incubation with Nodal resulted in a decrease in the level of phosphorylated FoxO3a and an increase in total FoxO3a expression in IOSE-398 and OV2008 (Figure 4a ). The Nodal treatment also induced Smad2 and 3 phosphorylation but inhibited AKT phosphorylation (Figure 4a ). Similar results were obtained when OV2008 cells were transfected with Nodal, ALK7ca or ALK4ca (Figure 4a ). Furthermore, both subcellular fractionation followed by immunoblotting and immunofluorescent studies revealed that Nodal, ALK7ca and ALK4ca transfection resulted in a nuclear retention of FoxO3a (Figure 4b ). To examine whether Nodal also enhances FoxO3a activity by regulating its gene expression, we measured FoxO3a mRNA and protein levels. Incubation with rhNodal or transfection with Nodal plasmid DNA increased, whereas silencing of endogenous ALK7 or Smad4 using small interfering RNAs (siRNAs) decreased, FoxO3a protein levels (Figure 4c ). Furthermore, FoxO3a mRNA level was also induced by rhNodal treatment in IOSE398 in several ovarian cancer cell lines, including OV2008, Skov3 and ES2, with the largest increase observed in IOSE398 cells (Figure 4d ).
Nodal promotes the association of Smads and FoxO3a as well as the binding of FoxO3a to the CCNG2 promoter As two putative SBEs (À507 to À504 bp and À352 to À349 bp) are located within 100 nt upstream and downstream of the functional FBE1 on the proximal promoter region (Figure 3a) , we tested if Smad proteins transcription. OV2008 cells were transfected with a full-length CCNG2 promoter construct, luciferase vectors, together with a control pCS2 (EV) or a pCS2 containing complementary DNA (cDNA) encoding mature Nodal (300 ng per well). Luciferase assays were performed at 24 h after transfection. Nodal expression in cell and secretion into the culture medium were confirmed by western blot. (b) Constitutively active ALK7 (ALK7ca) and ALK4 (ALK4ca)-induced CCNG2 promoter activity. Cells were transfected with control (EV), ALK7ca or ALK4ca (300 ng per well) and luciferase assays were performed as in (a). (c) Nodal increased CCNG2 mRNA levels. OV2008 cells were treated with rhNodal (500 ng/ml) for 24 h and CCNG2 mRNA was measured by real-time PCR. (d) Nodal increased CCNG2 protein levels. IOSE 398 cells were treated with rhNodal (500 ng/ml), LY294002 (10 mM) and SB431542 (10 mM) and cell lysates were prepared at 24 h after treatment. Bars denoted by different letters represent a significant difference at Po0.05.
and FoxO3a interact to regulate CCNG2 transcription. Overexpression of Smad2 or Smad3 significantly enhanced FoxO3a-induced CCNG2 promoter activities (Figure 5a ). Conversely, silencing of Smad4 expression using siRNA significantly decreased the basal and FoxO3a-induced (Figure 5b ), as well as Nodal-, ALK7ca-and ALK4ca-induced ( Figure 5c ) CCNG2 promoter activity and mRNA expression. Co-immunoprecipitation (IP) revealed that exogenously expressed FoxO3a is able to form a complex with exogenously expressed Smad3 and Smad4 in HEK293T cells (Figure 6a ). Consistently, this physical interaction between endogenous Smad4 and endogenous FoxO3a proteins was also detected and found to be induced in response to Nodal treatment in OV2008 cells (Figure 6b ). Association of FoxO3a and Smad4 was also enhanced by Nodal, ALK7ca or ALK4ca transfection ( Figure 6b , lower panel).
To investigate whether Nodal regulates FoxO3a binding to the CCNG2 promoter, chromatin-IP (ChIP) assays were performed using primers specific for FBE1 containing fragment (Figure 7a ). First, binding of FoxO3a to FBE1 region in OV2008 cells was confirmed by ChIP assay using an anti-FoxO3a antibody ( Figure 7b ). In the same experiment, PCR signal was also detected in the samples immunoprecipitated by the Smad2, 3 and 4 antibodies ( Figure 7b ). Interaction between FoxO3a and the FBE1 was further confirmed using exogenously expressed FoxO3a. In cells transfected with FoxO3a-WT or FoxO3a-AAA, PCR signals were detected following ChIP with an anti-Flag antibody ( Figure 7c ). Finally, to further examine whether the binding to the CCNG2 promoter is responsive to Nodal signaling, Nodal or empty vector was transfected into OV2008 cells followed by ChIP assay. FoxO3a binding to FBE1 region was significantly increased by Nodal overexpression as measured by both regular and quantitative real-time PCR (Figure 7d ).
FoxO3a mediates the action of Nodal/ALK7 on CCNG2 gene expression and cell proliferation Our observations that mutation of FBE1 abolished Nodal-induced CCNG2 transcription and that Nodal and its receptors upregulated FoxO3a activity suggest that FoxO3a mediates Nodal signaling to induce CCNG2 gene transcription. To confirm this possibility, RNA interference studies were carried out to knockdown endogenous FoxO3a expression using FoxO3a-specific siRNA (Figure 8a Figure 4 Nodal signaling enhances FoxO3a activity. (a) Nodal and its receptors activated Smad2/3 and inhibited AKT activation and FoxO3a inactivation. Left panels: IOSE398 and OV2008 cells were treated with or without rhNodal for 1 h after a 6-h starvation. Western blotting was done using various antibodies as indicated. Right panels: OV2008 cells were transfected with Nodal, ALK7ca, ALK4ca or their empty vector (EV) control for 6 h followed by a 12-h recovery. The expression of exogenous Nodal, ALK7ca and ALK4ca was confirmed by immunoblotting. (b) Nodal and its receptors induced FoxO3a accumulation in the nucleus. OV2008 cells were transfected with empty vector control, Nodal, ALK4ca or ALK7ca for 6 h. After 12-15-h recovery in culture medium, cells were subjected to subcellular fractionation (left panel) and immunofluorescence (right panel). In the left panel, Nodal, ALK7ca or ALK4ca increased FoxO3a levels in the nucleus and reduced the phosphorylated FoxO3a (pFoxO3a) level in the cytoplasm. As a positive control, Nodal also induced the accumulation of Smad2, 3 and 4 in the nucleus. The expression of Nodal, ALK7ca or ALK4ca in the cytoplasm was confirmed by antibodies against Nodal, c-Myc and HA and the blots were reprobled with Lamin B and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibodies to show loading controls. In the right panel, in EV-transfected cells and in non-transfected cells, FoxO3a signals were mainly observed in the cytoplasm. However, in Nodal-transfected group and in ALK4/7-transfected cells, FoxO3a was mainly found in the nucleus. ALK7ca-or ALK4ca-transfected cells were subjected to double immunofluorescence with FoxO3a antibody (red signal) and c-Myc or HA antibody (green signal to identify transfected cells). ( Figure 8b) . Similarly, in the presence of FoxO3a siRNA, rhNodal failed to induce CCNG2 promoter activity (Figure 8c ). These findings confirmed that FoxO3a is a necessary component to maintain the basal level and Nodal-induced CCNG2 gene transcription.
To further examine the functional relevance of the FoxO3a in mediating the effect of Nodal, WST-1 assays were performed. First, consistent with Nodal and ALK7ca (Figure 9a ), FoxO3a-WT and FoxO3a-AAA significantly decreased the number of viable cells (Figure 9b ). In contrast, FoxO3a siRNA increased cell viability and also reversed the growth inhibitory effect of Nodal and LY294002 (Figure 9c ). BrdU assays further showed that silencing of CCNG2 expression using siRNA (Figure 9d ) significantly increased cell proliferation. Consistent with the WST-1 results, Nodal and ALK7ca (Figure 9e) , as well as FoxO3a-WT and FoxO3a-AAA (Figure 9f ), inhibited cell proliferation Nodal induces cyclin G2 transcription via FoxO3a G Fu and C Peng and this effect was blocked when CCNG2 was knockdown by siRNA.
Discussion
We have previously reported that Nodal exerts inhibitory effects on ovarian cancer cell proliferation and that Physical interaction between endogenous FoxO3a and Smad4 in OV2008 cells was induced by Nodal. OV2008 cells were treated with rhNodal for 1 h after serum starvation for 12 h. IP was performed using anti-FoxO3 or anti-Smad4 antibody. In separated experiments, cells were transfected with control, Nodal, ALK7ca or ALK4ca for 6 h. After recovery for 15 h, cell lysate was harvested and IP using an antibody against Smad4, followed by immunoblotting with FoxO3a, Smad2, 3 and 4 antibodies. Immunoglobulin G (IgG) IP control was also included with pooled cell lysate from each group.
Nodal induces cyclin G2 transcription via FoxO3a G Fu and C Peng
CCNG2 is a target gene of Nodal. In this study, we further investigated the molecular mechanisms by which Nodal regulates CCNG2 expression. We demonstrated that Nodal-induced CCNG2 transcription by upregulating FoxO3a expression, inhibiting its inactivation by the PI3K pathway and enhancing its association with Smads, which in turn, binds to a functional FBE on the CCNG2 promoter ( Figure 10 ). We also provided evidence that regulation of FoxO3a activity is an important event for Nodal signaling to induce CCNG2 expression and inhibit cell proliferation.
Several studies have shown that CCNG2 mRNA levels and/or protein levels are upregulated by growth inhibitory signals, including TGF-b (Horne et al., 1997) and downregulated by oncogenic pathways, such as PI3K-AKT in murine NIH 3T3 cells (Martinez-Gac et al., 2004) , HER2, c-jun NH2-terminal kinase and the mammalian target of rapamycin/p70S6K (Le et al., 2007) , and estrogen signaling (Stossi et al., 2006) in breast cancer cells. In immortalized ovarian surface epithelial and ovarian cancer cells, Nodal increased CCNG2 mRNA and protein levels, as well as CCNG2 protein stability (Xu et al., 2008) . Here, we provided evidence that Nodal also induces CCNG2 expression at the level of transcription. Using luciferase assays, we found that Nodal and its constitutively active receptors, ALK4ca and ALK7ca, increased CCNG2 promoter activity.
FoxO3a is implicated in the regulation of a variety of cellular processes and cancer progression. It functions as a tumor suppressor by regulating many genes that control diverse biological activities, including cell proliferation (Dijkers et al., 2000; Hauck et al., 2007) and apoptosis (Sunters et al., 2003; Li et al., 2007) . In this study, we found that overexpression of FoxO3a induced, while silencing of FoxO3a decreased, CCNG2 promoter activity. A canonical FoxO-binding site, FBE3 and two putative FBEs, one containing a core motif (5 0 -AAACA-3 0 ) and the other (FBE1) containing three clustered core motifs, were found on the CCNG2 promoter. Deletion of FBE1 region in the proximal promoter, but not the other two FBEs, resulted in a dramatic decrease in both basal-and FoxO3a-induced CCNG2 transcription, suggesting that FoxO3a binding to this region is important for CCNG2 transcription. This notion is further supported by mutagenesis study in which mutation of FBE1 abolished the effect of FoxO3a on CCNG2 transcription. Finally, ChIP assays provided direct evidence that endogenous and exogenous FoxO3a can bind directly to the FBE1. Unlike the nonfunctional FBE3 and FBE2, which contain only one core motif, the functional FBE1 site harbors three core motifs, suggesting that clustered core motifs in a non-canonical FBE1 site may enhance the affinity of FoxO3a to the DNA. In addition, the functional FEB1 site is flanked by several binding sites for other transcription factors, such as Smads, AP2 and Sp1, it is possible that interaction between FoxO3a and these transcription factors is important for the binding of FoxO3a to the FBE1. Indeed, we have observed that FoxO3a can interact with Smad2, 3 and 4 to regulate CCNG2 transcription. A recent study also showed that Sp1 overexpression enhanced CCNG2 expression (Marshall et al., 2010) . Collectively, these results show that FoxO3a binds to the FBE1 region to induce CCNG2 transcription. Our finding that FoxO3a is a transcriptional activator of human CCNG2 is consistent with data from mouse studies (Martinez-Gac et al., 2004; Chen et al., 2006) .
It has been reported that Smad and forkhead transcription factors interact to regulate the expression of their target genes (Gomis et al., 2006b) . FoxO3a acts as a co-activator of Smad to regulate p21 expression and Nodal induces cyclin G2 transcription via FoxO3a G Fu and C Peng mediate the cytostatic effect of TGF-b in glioblastoma cells (Seoane et al., 2004) . In this study, we found that overexpression of Smad2 and 3 enhanced, while silencing of Smad4 decreased, the effect of FoxO3a on CCNG2 transcription. IP experiments revealed that Smad4 and FoxO3a formed a complex and this interaction was enhanced by Nodal signaling. Moreover, ChIP results showed that Nodal promoted the binding of FoxO3a to the FEB1 region. Therefore, it is possible that under Nodal stimulation, FoxO3a and Smad2/3/4 form a complex and this facilitates FoxO3a binding to the DNA, resulting in an increase in CCNG2 transcription. Several SBEs are located in the CCNG2 promoter. Deletion of the distal portion, which contains the first three SBEs did not interrupt the Nodalregulated CCNG2 promoter activity. This result is not surprising as it has been reported that Smad proteins do not efficiently bind to a single SBE on promoters because of the low affinity (Gomis et al., 2006a) . Although we did not attempt to characterize the functional SBE site in this study, it is possible that the two SBEs, located in close proximity to the FBE1, contribute to Nodal-induced CCNG2 transcription.
In addition to facilitate Smad/FoxO3a interaction, we found that Nodal also increased FoxO3a expression and inhibited its inactivation. FoxO3a is inactivated by phosphorylation and subsequent translocated from nucleus to cytoplasm. In this study, we showed that Nodal and its receptors suppressed the phosphorylation of AKT Ser473 , inhibited the phosphorylation of FoxO3a
Ser318/321 and induced the accumulation of FoxO3a in the nucleus, suggesting that the Nodal signaling pathway can inhibit the PI3K-AKT pathway to prevent FoxO3a inactivation. In addition to posttranslational modulation of FoxO3a activity, we further observed that Nodal-induced FoxO3a mRNA expression in IOSE-398 and several ovarian cancer cell lines. Induction of FoxO3a expression by Nodal is also confirmed by western blot analyses, which showed that Nodal increased, whereas silencing of ALK7 and Smad4 decreased, FoxO3a protein levels. Taken together, these results suggest that FoxO3a is a novel target gene of Nodal. The mechanism by which Nodal regulates FoxO3a expression remains to be investigated. However, as silencing Smad4 reduced FoxO3a expression, it is likely that Nodal acts through the canonical Smad pathway to regulate FoxO3a transcription.
The direct link between Nodal signaling and activation of FoxO3a expression and activity suggests that FoxO3a is a mediator of Nodal signaling pathway in ovarian cancer cells. Indeed, we observed that overexpression of FoxO3a mimicked, while silencing of FoxO3a reversed, the effect of Nodal on cell proliferation. Moreover, silencing of CCNG2 increased cell proliferation and abolished the inhibitory effect of FoxO3a and Nodal on cell proliferation. These findings demonstrate that FoxO3a and CCNG2 mediate, at least in part, the antiproliferative effect of Nodal. In addition to inhibit proliferation, the Nodal-ALK7 pathway also induces apoptosis in ovarian cancer and several other types of cells Wang et al., 2006; Zhang et al., 2006) . Similarly, a role for FoxO3a in the induction of apoptosis is well established (Huang and Tindall, 2007) . Interestingly, a recent study suggests that activation of FoxO3a is sufficient to reverse chemoresistance in human cancer (Yang et al., 2010) . In ovarian cancer cells, we have also observed that knockdown of ALK7 promoted chemoresistance whereas overexpression of ALK7 enhanced sensitivity of cancer cells to cisplatin (Ye et al., 2011) . More work is required to define the role of FoxO3a in Nodal/ALK7-regulated apoptosis and chemosensitivity.
To date, knowledge of how Nodal signaling has a role in cancer progression remains largely incomplete. Our earlier work on immortalized ovarian surface epithelial cells and some ovarian cancer cell lines showed that Nodal and ALK7 inhibit proliferation and induce apoptosis . The present findings that Nodal-induced CCNG2 transcription by upregulating FoxO3a expression, suppressing AKT phosphorylation and increasing FoxO3a activity are also consistent with the anti-proliferation and apoptosis-inducing effects of Nodal. However, Nodal was found to promote tumor progression in melanoma cells (Topczewska et al., 2006) . We have also performed experiments to compare the effect of Nodal on OV2008 and U87 (a glioblastoma cell line) and found that Nodal exerts opposite effects on cell proliferation in these two cell lines (De Silva and Peng, unpublished results). Thus, it is possible that the effect of Nodal on cancer progression is also very complex and depends on such factors as the cellular environment, the type of cancer and/or the stage of tumor development. The complexity of TGF-b signaling in cancer progression is well documented with both tumor-suppressing and tumor-promoting effects (Derynck et al., 2001) . Interestingly, a recent study suggests that CCNG2 may have metastasis-suppressive effects and that downregulation of CCNG2 is involved in TGF-b-induced breast cancer metastasis (Adorno et al., 2009) . It remains to be determined whether Nodal differentially regulates CCNG2 to exerts tumorsuppressing and tumor-promoting effects.
Human epithelial ovarian cancer is the most lethal gynecological malignancy diagnosed among women worldwide and the fifth leading cause of cancer death (Naora and Montell, 2005) . It has been reported that low expression of FoxO3a in ovarian cancer is associated with poor prognosis of patients (Fei et al., 2009) . Higher CCNG2 expression also correlates with recurrence-free survival in breast cancer patients (Adorno et al., 2009) . Therefore, future studies to fully characterize the potential dysregulation of Nodal, CCNG2 and FoxO3a during ovarian cancer progression will improve our understanding of this devastating disease and may reveal novel therapeutic targets.
In summary, we have identified a novel mechanism by which Nodal signaling inhibits cell proliferation: Nodal regulates CCNG2 transcription through the induction of FoxO3a expression, the inhibition of FoxO3a inactivation by AKT, and the promotion of interaction between FoxO3a and Smad proteins. We have characterized a functional FoxO3a-binding site in the CCNG2 promoter region, through which FoxO3a and Smads, activated by Nodal signaling, were able to promote CCNG2 gene transcription (Figure 10 ). Whether or not induction of FoxO3a expression by Nodal involves transcriptional regulation via the Smad pathway remains to be investigated. Figure 10 Proposed mechanisms by which the Nodal signaling pathway regulates FoxO3a and CCNG2. Nodal induces FoxO3a activity by inhibiting the PI3K-AKT pathway, leading to accumulation of FoxO3a in the nucleus. Nodal also activates its canonical Smad signaling pathway and promotes the association of Smads with FoxO3a, which in turn, binds to the CCNG2 promoter to stimulate its transcription. In addition, the Nodal pathway also promotes FoxO3a gene expression. Whether or not this regulation occurs through a mechanism involving transcriptional regulation by the Smads requires further investigation.
Materials and methods
Reagents and plasmids rhNodal was purchased from R&D System (Minneapolis, MN, USA). SB431542 and LY294002 were purchased from Sigma-Aldrich (Oakville, ON, Canada). Human full-length Nodal, ALK7ca expression plasmid in a c-Myc-tagged pcDNA4 and Smad2, Smad3 and Smad4 plasmids in pcDNA3 were established or obtained as previously described . ALK4ca expression plasmid in HA-tagged pCMV5 was kindly provided by Dr Liliana Attisano (University of Toronto, ON, Canada). A plasmid expressing only the mature peptide of Nodal in pCS2 þ (Tian et al., 2008) was kindly provided by Dr Karuna Sampath (Nanyang Technological University, Singapore). Human Flag-tagged FoxO3a-WT and FoxO3a-AAA in a pcDNA3 vector (Ramaswamy et al., 2002) were obtained from Addgene (Cambridge, MA, USA). A plasmid expressing CCNG2 siRNA was generated as previously reported (Xu et al., 2008) .
Cell culture and transfection
Ovarian cancer cell line OV2008 cells and immortalized ovarian surface epithelial cells (IOSE-398) were obtained and cultured as previously described . Human ovarian carcinoma cell lines Skov-3 and ES-2 cell lines (ATCC, Rockville, MD, USA) were grown in McCoy's 5a medium with 10% FBS and 1.5 mM L-glutamine. Transient transfection was carried out using Lipofectamine 2000 (Invitrogen Canada Inc., Burlington, ON, Canada) according to the manufacturer's suggested protocols.
Cloning of CCNG2 promoter constructs
The 1581-bp DNA fragment containing the sequence from þ 90 to À1491 bp of the CCNG2 gene promoter, referred as F6, was amplified by PCR using genomic DNA as the template. The genomic DNA was extracted from IOSE398 cells using a QIAamp DNA mini kit (QIAGEN, Mississauga, ON, Canada). PCR was performed using a reverse primer carrying a NheI site, RP and a forward primer carrying a Sac I site, FP6 and pfu turbo DNA polymerase (NEB Lab, Pickering, ON, Canada). The resulting DNA fragment was subcloned into pGL4 basic (Promega, Sunnyvale, CA, USA). The same reverse primer and a forward primer, FP1 to FP5, were used to make deletion constructs F1 to F5. A construct containing the mutated FBE1 was generated using the Quick Change multi site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA). Primer sequences are listed in Supplementary Table 1 .
Real-time PCR analysis of CCNG2 and FoxO3a mRNA Total RNA was extracted using Trizol reagent (Invitrogen Canada Inc., Burlington, ON, Canada) and reversed transcribed to complementary DNA using oligo(T)23VN primer (SigmaAldrich). Quantitative reverse transcriptase-PCR was carried out using gene-specific primers for CCNG2 and FoxO3a and SYBR Green Master Mix (Bio-Rad, Mississauga, ON, Canada). Expression levels of glyceraldehyde-3-phosphate dehydrogenase were also determined as an internal control. Primer sequences are listed in Supplementary Table 1.
Co-transfection and luciferase report assay Cells were co-transfected with a CCNG2 promoter construct, firefly luciferase, Renilla luciferase and in some cases, FoxO3a-WT, FoxO3a-AAA, Nodal, ALK7ca, ALK4ca or their empty vector control (100 ng-300 ng per well) in a 24-well cell culture plate. Following 6-h transfection and 24-h recovery, cells lysates were harvested in passive lysis buffer and all luciferase activities were quantified using the Dual-Luciferase Reporter Assay system (Promega). Relative luciferase activity was calculated as the ratio of firefly/renilla luciferase.
Western blot analysis, subcellular fractionation and IP Whole-cell extracts were prepared in radioimmunoprecipitation assay buffer supplemented with protease and phosphatase inhibitor cocktails (Thermo Scientific, Rockford, IL, USA). Western blotting was carried out using antibodies of pSmad2, pSmad3, total Smad2/3, pAKT (Ser473), total AKT and phosphorylated FoxO3a (Ser318/321) (Cell Signaling, Danvers, MA, USA), FoxO3a (Upstate Biotechnology, Temecula, CA, USA), CCNG2 and Smad4 (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Protein bands were visualized with SuperSignal (Pierce, Rockford, IL USA). The membranes were lastly re-probed with an anti-b-actin antibody (SigmaAldrich) as loading controls. Subcellular fractionation was carried out using the NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientific). Briefly, after 6-h transfection and 12-h recovery, OV2008 cells were harvested by Trypsin-EDTA and cytoplasmic and nuclear proteins extracted according to the product instructions. IP was performed as previously described (Xu et al., 2008) using anti-Flag (1:100), anti-FoxO3a (2 mg), anti-Smad4 (1:100) or anti-rabbit immunoglobulin G (1:100, Santa Cruz Biotechnology) at 4 1C for 16 h. After further incubation with protein G/A agarose beads (GE Healthcare, Waukesha, WI, USA) at 4 1C for 3 h, the complexes were collected by centrifugation (10 000 Â g), washed three times with IP buffer and eluted into 30 ml 2 Â sodium dodecyl sulfate sample buffer.
Immunofluorescence and microscopy Cells were fixed with cold methanol/acetone (1:1 volume), permeabilized with 0.2% Triton X-100 and then incubated with anti-FoxO3a antibody (1:200) in phosphate-buffered saline containing 1% bovine serum albumin. To verify transfected cells, anti-c-Myc or -HA antibody (1:300) was also used. Secondary antibodies used were Alexa Fluor 594 goat anti-rabbit or Alexa Fluor 488 goat anti-mouse immunoglobulin G (1:200, Molecular Probes, Eugene, OR, USA). Microscopy was performed using a Nikon Eclipse TE2000-U fluorescence microscope (Nikon, Melville, NY, USA).
RNA interference
Small interference RNA (50 nM) was transfected into cells for 24 h using Lipofectamine 2000. To confirm gene-specific silencing effects, protein lysates were prepared at 48 h after transfection and subjected to western blot analysis. ALK7, FoxO3a and Smad3 siRNAs (see Supplementary Table 1 for sequences) and a scrambled control siRNA, which has no significant homology to any mammalian gene sequence (Supplementary Table 1) were purchased from GenePharma Co. (Shanghai, China).
ChIP assay OV2008 cells (2.5 Â 10 6 cells), non-transfected or transfected with an empty pcDNA3 vector (Control), Flag-tagged FoxO3a-WT, FoxO3a-AAA or Nodal for 6 h followed by 15-h recovery in culture medium, were cross-linked by 37% formaldehyde for 10 min. The cells were then harvested and lysed with sodium dodecyl sulfate lysis buffer (1% sodium dodecyl sulfate, 10 mM EDTA, 50 mM Tris-Cl, pH8.1). The lysates were sonicated and pre-cleared by protein G agarose (GE Healthcare, Piscataway, NJ, USA). Anti-FoxO3a, anti-Smad2, anti-Smad3, antiSmad4 antibody (2 mg) or normal rabbit immunoglobulin G was added to the lysate and incubated at 4 1C overnight. The subsequent steps were performed as indicated in the EZ ChIP Chromatin Immunoprecipitation kit (Upstate, Charlottesville, VA, USA). The precipitated DNA was amplified by PCR using a Hotstart Taq DNA polymerase (Qiagen Sciences, Germantown, MD, USA) or iQ SYBR Green Supermix (Bio-Rad). A 183-bp fragment containing target FBE1 in the CCNG2 promoter was monitored using ChIP-FP1 and ChIP-RP1 primers (Supplementary Table 1) .
Cell viability and proliferation assay Cell viability was determined by WST-1 assays (Roche, Mississauga, ON, Canada) and cell proliferation was measured using BrdU assays (EMD Biosciences, Inc., La Jolla, CA, USA). OV2008 cells were plated in 96-well plate at the density of 0.5-1 Â 10 4 cells per well and transfected with various plasmid DNA or siRNAs. WST-1 or BrdU assays were performed according to the manufactory procedures and absorbance was measured at 450 nm using an enzyme-linked immunosorbent assay plate reader.
Statistical analysis
All data are presented as mean ± s.e.m. Each experiment was performed 3-5 times. Statistical analysis was done using Student's t-test for comparison between two groups or analysis of variance followed by a Tukey-Kramer test for multiple group comparison (Graph Pad InStat Software, San Diego, CA, USA). Groups denoted by different letters represent a significant difference at Po0.05.
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